Yasmin Schmid

Senior Attending Physician at University Hospital Basel

Data updated

Papers

26 publications

Trials

0 clinical trials

Research Footprint

Yasmin Schmid appears in 26 tracked papers (2013–2026), most studied alongside LSD, MDMA and Psilocybin, across Healthy Volunteers, Anxiety Disorders and Medicinal Chemistry & Drug Development.

Most-cited paper: Acute effects of lysergic acid diethylamide in healthy subjects (424 citations).

Frequent co-authors: Matthias Liechti, Patrick Dolder and Stefan Borgwardt.

Publication Landscape

How the 26 papers Blossom tracks for Yasmin Schmid line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.

How has Yasmin Schmid's publishing grown?

Sourced

Tracked papers by publication year. Click a year for the running total.

7papers published in 2017

+133% vs 2016

13 published by 2017

Browse papers→

Don't read as total output: only the 26 of 26 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.

What does Yasmin Schmid publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Anxiety Disorders
10
Medicinal Chemistry & Drug Development
8
Depressive Disorders
7
Interpersonal Functioning & Social Connectedness
6
Personality & Trait Factors
4
PTSD
4
Addiction & Substance Use
3
Neuroimaging & Brain Measures
3
Other
17

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.

Where does Yasmin Schmid publish?

Sourced

Tracked papers per journal. Orange marks the most-used journal.

Psychopharmacology
5
Translational Psychiatry
3
International Journal of Neuropsychopharmacology
2
Clinical Pharmacokinetics
2
Cell Reports
1
Biological Psychiatry
1
Journal of Neuroendocrinology
1
Drug Testing and Analysis
1
Other
10

Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.

Background & Research

Dr. Yasmin Schmid is a leading expert in the clinical pharmacology of serotonergic psychedelics. Her research at the University of Basel characterizes the acute and long-lasting effects of LSD and MDMA in both healthy volunteers and patients. She focus on the safety, efficacy, and neurobiological mechanisms that underpin the therapeutic potential of these substances in palliative care and psychiatry.

Key Impact

Clinical pharmacologist specializing in the safety and dose-response profiles of LSD and MDMA.

26

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

33 collaborators· click a node to visit their profile

Full network →

Collaboration Network

See Yasmin Schmid's full collaboration network, shared papers, and research connections.

Compounds

LSDMDMAPsilocybinMescalinePlacebo

Topics

Healthy VolunteersAnxiety DisordersMedicinal Chemistry & Drug DevelopmentDepressive DisordersInterpersonal Functioning & Social ConnectednessPersonality & Trait FactorsPTSDMajor Depressive Disorder (MDD)Neuroimaging & Brain MeasuresSubstance Use Disorders (SUD)Palliative & End-of-Life DistressOlder AdultsSet & SettingPublic Health, Prevention & Behaviour ChangeHeadache Disorders (Cluster & Migraine)Chronic PainSchizophreniaObsessive-Compulsive Disorder (OCD)AdolescentsTobacco/Nicotine Use Disorder (TUD)Equity and EthicsMicrodosingSafety & Risk Management

Top Collaborators

Top Collaborators

Unlock clinical summaries, full texts, and related trial mapping.

Affiliations

Institutions, companies, and organisations Yasmin Schmid is associated with.

University of Basel

academic

The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.

View stakeholder →